Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas Theodosakis

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Molecular Cancer Therapeutics|May 8, 2015
BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell VolumeNicholas Theodosakis, Matthew A Held, Alexander Marzuka-Alcala, et al.
The Oncologist|March 30, 2021
Risk of COVID-19 in Patients with Cancer Receiving Immune Checkpoint InhibitorsNikolai Klebanov, Vartan Pahalyants, William S Murphy, et al.
The Journal of Thoracic and Cardiovascular Surgery|January 22, 2009
Fluorodeoxyglucose positron emission tomography and tumor marker expression in non-small cell lung cancerMatthew D Taylor, Philip W Smith, William K Brix, et al.
JAMA Dermatology|January 7, 2026
Validation of International Classification of Diseases Codes for Dermatologic Conditions: A Systematic ReviewDebby Cheng, Nora Bensellam, Katherine Sanchez, et al.
Oncotarget|October 21, 2015
SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cellsCasey G Langdon, Norbert Wiedemann, Matthew A Held, et al.
Journal for Immunotherapy of Cancer|June 15, 2022
Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort studyBruce C Tiu, Leyre Zubiri, James Iheke, et al.
Cancer Cell|January 14, 2015
mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formationWilliam Damsky, Goran Micevic, Katrina Meeth, et al.
Science Advances|April 3, 2021
Reduced MC4R signaling alters nociceptive thresholds associated with red hairKathleen C Robinson, Lajos V Kemény, Gillian L Fell, et al.
Journal of the American Academy of Dermatology|February 24, 2023
Influence of melanoma type on incidence and downstream implications of cutaneous immune-related adverse events in the setting of immune checkpoint inhibitor therapyNga Nguyen, Guihong Wan, Pearl Ugwu-Dike, et al.
Biorxiv : the Preprint Server for Biology|December 25, 2025
UV induces common cutaneous amyloid-like melanosomal protein aggregatesNicholas Theodosakis, Porter B Howland, Miroslav Hejna, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Molecular Cancer Therapeutics|May 8, 2015
BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell VolumeNicholas Theodosakis, Matthew A Held, Alexander Marzuka-Alcala, et al.
The Oncologist|March 30, 2021
Risk of COVID-19 in Patients with Cancer Receiving Immune Checkpoint InhibitorsNikolai Klebanov, Vartan Pahalyants, William S Murphy, et al.
The Journal of Thoracic and Cardiovascular Surgery|January 22, 2009
Fluorodeoxyglucose positron emission tomography and tumor marker expression in non-small cell lung cancerMatthew D Taylor, Philip W Smith, William K Brix, et al.
JAMA Dermatology|January 7, 2026
Validation of International Classification of Diseases Codes for Dermatologic Conditions: A Systematic ReviewDebby Cheng, Nora Bensellam, Katherine Sanchez, et al.
Oncotarget|October 21, 2015
SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cellsCasey G Langdon, Norbert Wiedemann, Matthew A Held, et al.
Journal for Immunotherapy of Cancer|June 15, 2022
Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort studyBruce C Tiu, Leyre Zubiri, James Iheke, et al.
Cancer Cell|January 14, 2015
mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formationWilliam Damsky, Goran Micevic, Katrina Meeth, et al.
Science Advances|April 3, 2021
Reduced MC4R signaling alters nociceptive thresholds associated with red hairKathleen C Robinson, Lajos V Kemény, Gillian L Fell, et al.
Journal of the American Academy of Dermatology|February 24, 2023
Influence of melanoma type on incidence and downstream implications of cutaneous immune-related adverse events in the setting of immune checkpoint inhibitor therapyNga Nguyen, Guihong Wan, Pearl Ugwu-Dike, et al.
Biorxiv : the Preprint Server for Biology|December 25, 2025
UV induces common cutaneous amyloid-like melanosomal protein aggregatesNicholas Theodosakis, Porter B Howland, Miroslav Hejna, et al.
Pageof 6